MAUDE Adverse Event Report: BAYER PHARMA AG ESSURE; TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE

Model Number ESS205

Device Problems Adverse Event Without Identified Device or Use Problem (2993); Appropriate Term/Code Not Available (3191)

Patient Problem Pain (1994)

Event Type  Injury  

Event Description

This spontaneous case was originally reported by a lawyer on behalf of a consumer and describes the occurrence of pelvic pain ("pelvic pain severe long") in a female patient who had essure inserted.Additional non-serious events are detailed below.Product or product use issues identified: device failure, defect ("failure defect (incl other organ damage)").There was no information on the patient's medical history or concurrent conditions.In (b)(6) 2006, the patient had essure inserted.On unknown dates she experienced pelvic pain (seriousness criterion intervention required), abnormal uterine bleeding ("abnormal uterine bleeding minimal, medium"), sexual dysfunction ("sexual dysfunction severe long") and injury ("failure defect (incl other organ damage)").The patient was treated with surgery (essure removal via bilateral salpingectomy).Essure was removed.At the time of the report, the outcomes for these events were unknown.The reporter considered abnormal uterine bleeding, injury, pelvic pain and sexual dysfunction to be related to essure administration.The reporter commented: patient intends to remove essure, on follow-up (b)(6) 2022 was reported the essure was removed.Adverse events impact on her lifestyle.Quality-safety evaluation of ptc: for essure: unable to confirm complaint.The most recent follow-up information incorporated above includes data received on: 07-feb-2023: the information was received on 27-dec-2022, the seriousness were updated to serious-incident, and the follow information were included non-drug treatment, essure removal via removal via bilateral salpingectomy added on pelvic pain female, imdrf code updated.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.

Manufacturer Narrative

This spontaneous case was originally reported by a lawyer on behalf of a consumer and describes the occurrence of pelvic pain ("pelvic pain severe long") in a female patient who had essure inserted.Additional non-serious events are detailed below.Product or product use issues identified: device failure, defect ("failure defect (incl other organ damage)").There was no information on the patient's medical history or concurrent conditions.In (b)(6) 2006, the patient had essure inserted.On unknown dates she experienced pelvic pain (seriousness criterion intervention required), abnormal uterine bleeding ("abnormal uterine bleeding minimal, medium"), sexual dysfunction ("sexual dysfunction severe long") and injury ("failure defect (incl other organ damage)").The patient was treated with surgery (essure removal via bilateral salpingectomy).Essure was removed.At the time of the report, the outcomes for these events were unknown.The reporter considered abnormal uterine bleeding, injury, pelvic pain and sexual dysfunction to be related to essure administration.The reporter commented: patient intends to remove essure, on follow-up 27-dec-2022 was reported the essure was removed.Adverse events impact on her lifestyle.Quality-safety evaluation of ptc: for essure: unable to confirm complaint.The following amendment was made: the received date of last followup was amended, the correct of follow-up received was on 27-jan-2023.No new follow-up information was received from the reporter.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.

Manufacturer Narrative

This spontaneous case was originally reported by a lawyer on behalf of a consumer and describes the occurrence of pelvic pain ("pelvic pain severe long") in a female patient who had essure (ess205) inserted.Additional non-serious events are detailed below.Product or product use issues identified: device failure, defect ("failure defect (incl other organ damage)".There was no information on the patient's medical history or concurrent conditions.In (b)(6) 2006, the patient had essure (ess205) inserted.On unknown dates she experienced pelvic pain (seriousness criterion intervention required), abnormal uterine bleeding ("abnormal uterine bleeding minimal, medium"), female sexual dysfunction ("sexual dysfunction severe long") and injury ("failure defect (incl other organ damage)").The patient was treated with surgery (essure removal via bilateral salpingectomy).Essure (ess205) was removed.At the time of the report, the outcomes for these events were unknown.The reporter considered abnormal uterine bleeding, female sexual dysfunction, injury and pelvic pain to be related to essure (ess205) administration.The reporter commented: patient intends to remove essure, on follow-up (b)(6) 2022 was reported the essure was removed.Adverse events impact on her lifestyle.Quality-safety evaluation of ptc: for essure (ess205): no defect could be confirmed by the manufacturer.All product batches have met the specifications regarding labeling, material, and process controls at time of release.Trend analyses of complaints are reviewed regularly, no signal was observed with regard to the reported complaint reason.The risk management file was reviewed and an update was not deemed required.A technical investigation of the complaint sample and batch record review could not be conducted, as no sample or batch number were available.The most recent follow-up information incorporated above includes data received on: 14-mar-2023: quality safety evaluation of ptc.Based on the available information, a review of our complaint records and other relevant data was conducted; any new and reportable information that becomes available from our investigation will be provided in a supplementary report.

• Brand Name: ESSURE
• Type of Device: TRANSCERVICAL CONTRACEPTIVE TUBAL OCCLUSION DEVICE
• Manufacturer (Section D): BAYER PHARMA AG; müllerstr. 178; berlin, 13353 ; GM 13353
• Manufacturer (Section G): BAYER PHARMA AG; müllerstr. 178; berlin, 13353 ; GM 13353
• Manufacturer Contact: k shaw lamberson ; 100 bayer blvd, p.o. box 915; whippany, nj
• MDR Report Key: 16399469
• MDR Text Key: 309780879
• Report Number: 2951250-2023-00542
• Device Sequence Number: 1
• Product Code: HHS
• UDI-Device Identifier: 10888853003051
• UDI-Public: (01)10888853003051
• Combination Product (y/n): N
• Reporter Country Code: AU
• PMA/PMN Number: P020014
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: Other,Foreign,Consumer
• Reporter Occupation: Other
• Type of Report: Initial,Followup,Followup
• Report Date: 03/16/2023

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 02/17/2023
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Health Professional
• Device Model Number: ESS205
• Is the Reporter a Health Professional?: No
• Date Manufacturer Received: 03/14/2023
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Required Intervention
• Patient Sex: Female